Literature DB >> 820628

Pyruvate kinase isozymes in man. II. L type and erythrocyte-type isozymes. Electrofocusing and immunologic studies.

A Kahn, J Marie, P Boivin.   

Abstract

By focusing in sucrose, gradient L-type pyruvate kinase from human liver could be separated into 2 major forms (pI 6.28 +/- 0.03 and 5.85 +/- 0.09) and a minor more acid form (pI = 5). These different forms could also be detected by focusing in acrylamide-ampholine slab gel. The major forms were interconvertible, the equilibrium being shifted toward the acid form by fructose 1,6-diphosphate and SH reagents, and toward the alkaline form by proteinic factors extracted by ammonium sulphate fractionation from liver extracts and from hemolysates. These factors seemed to be responsible for the stabilization of the liver crude extract enzyme in its alkaline conformation. By acrylamide slab gel electrofocusing, erythrocyte pyruvate kinase from whole hemolysates exhibited a complex pattern composed of at least 3 introconvertible forms. The in vitro aging of the red blood cells and the storage of the hemolysates resulted in a progressive disappearance of the acid forms and in a strengthening of the alkaline form. Partially purified erythrocyte enzyme focused in 2 major bands, interconvertible under the influence of the same factors as those described for L-type pyruvate kinase. Although closely related, the focusing patterns of L-type and erythrocyte-type were never exactly identical. Double immunodiffusion against antihuman erythrocyte-and L-type pyruvate kinases. Moreover, antihuman M2-type serum was unable to neutralize erythrocyte pyruvate kinase as well as to change its electrophoretic mobility. Consequently, we conclude that both human erythrocyte- and liver L-type pyruvate kinases existed under several conformers interconvertible under the influence of the same ligands or proteinic factors; erythrocyte-type enzyme seems to include L-type subunit and not M1- or M2-type subunits. The erythrocyte- and L-type enzymes, however, are not identical and the nature of the differences between them is discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 820628     DOI: 10.1007/BF00447284

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  24 in total

1.  Further evidence of molecular alteration and aberration of erythrocyte pyruvate kinase.

Authors:  K Nakashima
Journal:  Clin Chim Acta       Date:  1974-09-16       Impact factor: 3.786

2.  Pyruvate kinase electrophoresis in normal and pyruvate kinase deficient hemolysates.

Authors:  B Wonneberger; W Schröter
Journal:  Clin Chim Acta       Date:  1974-03-15       Impact factor: 3.786

3.  Electrophoretic and kinetic studies of mutant erythrocyte pyruvate kinases.

Authors:  K Nakashima; S Miwa; S Oda; T Tanaka; K Imamura
Journal:  Blood       Date:  1974-04       Impact factor: 22.113

4.  Studies on pyruvate kinase (PK) deficiency. II. Electrophoretic, kinetic and immunological studies on pyruvate kinase of erythrocytes and other tissues.

Authors:  K Imamura; T Tanaka; T Nishina; K Nakashima; S Miwa
Journal:  J Biochem       Date:  1973-12       Impact factor: 3.387

5.  Human erythrocyte pyruvate kinase conformers obtained by electrofocusing.

Authors:  K H Ibsen; P Trippet
Journal:  Life Sci II       Date:  1971-09-22

6.  Liver pyruvate kinase (PK) isozymes in a PK-deficient patient.

Authors:  R H Bigley; R D Koler
Journal:  Ann Hum Genet       Date:  1968-05       Impact factor: 1.670

7.  Identification of two types of liver pyruvate kinase.

Authors:  B Hess; C Kutzbach
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1971-03

8.  Purification of human erythrocyte pyruvate kinase.

Authors:  C J Chern; M B Rittenberg; J A Black
Journal:  J Biol Chem       Date:  1972-11-25       Impact factor: 5.157

9.  [Erythrocyte isolation from blood with cotton].

Authors:  D Busch; K Pelz
Journal:  Klin Wochenschr       Date:  1966-08-15

10.  Pyruvate kinase isozymes in man. I. M type isozymes in adult and foetal tissues, electrofocusing and immunological studies.

Authors:  J Marie; A Kahn; P Boivin
Journal:  Hum Genet       Date:  1976-01-28       Impact factor: 4.132

View more
  5 in total

1.  Succinyl-5-aminoimidazole-4-carboxamide-1-ribose 5'-Phosphate (SAICAR) Activates Pyruvate Kinase Isoform M2 (PKM2) in Its Dimeric Form.

Authors:  Ming Yan; Srinivas Chakravarthy; Joshua M Tokuda; Lois Pollack; Gregory D Bowman; Young-Sam Lee
Journal:  Biochemistry       Date:  2016-08-11       Impact factor: 3.162

2.  A red cell pyruvate kinase mutant with normal L-type PK in the liver.

Authors:  J Etiemble; C Picat; P Boivin
Journal:  Hum Genet       Date:  1982       Impact factor: 4.132

3.  Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation.

Authors:  Jiangbin Ye; Anthony Mancuso; Xuemei Tong; Patrick S Ward; Jing Fan; Joshua D Rabinowitz; Craig B Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-16       Impact factor: 11.205

4.  Hereditary erythrocyte pyruvate-kinase (PK) deficiency and chronic hemolytic anemia: clinical, genetic and molecular studies in six new Spanish patients.

Authors:  J L Vives-Corrons; J Marie; M A Pujades; A Kahn
Journal:  Hum Genet       Date:  1980       Impact factor: 4.132

5.  The cellular and compartmental profile of mouse retinal glycolysis, tricarboxylic acid cycle, oxidative phosphorylation, and ~P transferring kinases.

Authors:  Elda M Rueda; Jerry E Johnson; Anand Giddabasappa; Anand Swaroop; Matthew J Brooks; Irena Sigel; Shawnta Y Chaney; Donald A Fox
Journal:  Mol Vis       Date:  2016-07-23       Impact factor: 2.367

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.